Apogee Therapeutics has entered into a strategic financing collaboration with funds managed by Blackstone Life Sciences for up to $1.3 billion in flexible, non-dilutive total capital to support the continued development and potential commercialisation of zumilokibart. Combined with company’s current total cash of $1.3 billion, the company… Read More
Research and development in medical dermatology is set to be advanced by supercomputing and artificial intelligence. Biopharmaceutical company Almirall has announced an expanded collaboration with the Barcelona Supercomputing Center (BSC), aiming to address the needs of patients with skin conditions. The partnership builds on previous successful R&D joint… Read More
Global pharmaceutical company Almirall has announced it will launch three clinical trials in 2026 to further advances in the medical dermatology field. Speaking at the 44th J.P. Morgan Healthcare Conference, which took place in San Francisco, Almirall CEO Carlos Gallardo said the company was focused on developing impactful novel… Read More
Takeda’s oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) has shown promise to deliver clear skin in a once-daily pill. Phase III studies in adults with moderate-to-severe plaque psoriasis (PsO) have demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA)… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Thibaud Portal, Founder… Read More
DDW speaks to Leanne Walsh, General Manager & VP at LEO Pharma UK & Ireland about her career in the pharmaceutical industry. Read More
Biopharmaceutical companies Almirall and Absci have announced an expansion of their ongoing partnership targeting dermatological indications. The expansion of the collaboration follows the successful delivery of AI-designed, functional antibody leads against a difficult-to-drug target—the first target addressed within the initial collaboration between Almirall and Absci. … Read More
LEO Pharma has initiated the Phase IIa proof-of-concept DELTA NEXT trial to evaluate the efficacy and safety of delgocitinib cream compared to cream vehicle for mild to severe Palmoplantar Pustulosis (PPP). “The DELTA NEXT trial in PPP represents an exciting new chapter in the clinical development journey… Read More
The University of Liverpool’s spin-out company, Galytx, has signed an exclusive licensing agreement with dermatology biotech Quodria. Together the companies plan to develop a first-in-class treatment for atopic dermatitis (AD), a form of eczema. Galytx, launched in June 2024, focuses on the development of galectin-3… Read More
The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP). The sBLA is supported by data from a pivotal study evaluating the efficacy and safety of Dupixent in… Read More
Icelandic drug discovery and development company Arctic Therapeutics (ATx) has announced the successful closing of a €26.5 million oversubscribed Series A financing from a syndicate of international investors. The syndicate includes the EIC Fund, Iceland’s largest privately-held investment firm Kaldbakur, Investcorp-backed Sanos Group, Swiss-based Cerebrum DAO, The… Read More
The US Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ENV-294 targeting atopic dermatitis and other inflammatory conditions. A Phase I clinical trial has since started for ENV-294, with the first patient dosed at the end of October. Read More
A Dupixent (dupilumab) pivotal study (ADEPT) in bullous pemphigoid (BP) has met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate-to-severe disease. In the study, five times more Dupixent patients achieved sustained disease remission compared to those on placebo. Read More
Glasgow, UK-based ILC Therapeutics has successfully completed a fundraise of £2.5 ($3.2) million. The company develops hybrid interferons, a new drug class engineered for improved therapeutic profiles across multiple indications. The money will support the continued pre-clinical development of the company’s two lead assets,… Read More
The first patient has been treated in a Phase II trial of EVO756 in adults with chronic inducible urticaria (CIndU). EVO756 is a highly selective small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2) and could offer the potential for once-daily oral administration without the… Read More
The Scottish Medicines Consortium (SMC) has published final advice on two rare disease therapies. Elfabrio (pegunigalsidase alfa), a novel enzyme replacement therapy (ERT), has been approved as a treatment option for Fabry disease in adults. Also, birch bark extract gel has been approved… Read More
